Team

Daisy Hoagland

PhD Candidate
EDUCATION AND TRAINING

BIOGRAPHY

Daisy is a 3rd year PhD student in the tenOever laboratory, focusing on researching the innate immune response to pandemic viruses, specifically SARS-CoV-2 and Influenza A virus. She earned her B.S. from the University of Vermont while researching pulmonary lung pathology in the Janssen-Heininger laboratory. Before coming to Mount Sinai, Daisy spent a year volunteering as an AmeriCorps VISTA with a STEM mentorship nonprofit.


PUBLICATIONS

The NF-κB transcriptional footprint is essential for SARS-CoV-2 replication

Nilsson-Payant BE, Uhl S, Grimont A, Doane AS, Cohen P, Patel RS, Higgins CA, Acklin JA, Bram Y, Chandar V, Blanco-Melo D, Panis M, Lim JK, Elemento O, Schwartz RE, Rosenberg BR, Chandwani R, tenOever BR

J Virol. 2021 Sep 15:JVI0125721 15/09/2021

PMID: 34523966

A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics.

Longlong Si # 1, Haiqing Bai # 1, Melissa Rodas 1, Wuji Cao 1, Crystal Yuri Oh 1, Amanda Jiang 1 2, Rasmus Moller 3, Daisy Hoagland 3, Kohei Oishi 3, Shu Horiuchi 3, Skyler Uhl 3, Daniel Blanco-Melo 3, Randy A Albrecht 3, Wen-Chun Liu 3, Tristan Jordan 3, Benjamin E Nilsson-Payant 3, Ilona Golynker 3, Justin Frere 3, James Logue 4, Robert Haupt 4, Marisa McGrath 4, Stuart Weston 4, Tian Zhang 5, Roberto Plebani 1 6, Mercy Soong 1, Atiq Nurani 1, Seong Min Kim 1, Danni Y Zhu 1, Kambez H Benam 1 7 8, Girija Goyal 1, Sarah E Gilpin 1, Rachelle Prantil-Baun 1, Steven P Gygi 5, Rani K Powers 1, Kenneth E Carlso n 1, Matthew Frieman 4, Benjamin R tenOever 3, Donald E Ingber 9 10.

Nature Biomedical Engineering 03/05/2021

PMID: 33941899

Common Genetic Variation in Humans Impacts In Vitro Susceptibility to SARS-CoV-2 Infection

Dobrindt K, Hoagland DA, Seah C, Kassim B, O'Shea CP, Murphy A, Iskhakova M, Fernando MB, Powell SK, Deans PJM, Javidfar B, Peter C, Møller R, Uhl SA, Garcia MF, Kimura M, Iwasawa K, Crary JF, Kotton DN, Takebe T, Huckins LM, tenOever BR, Akbarian S, Brennand KJ

Stem Cell Reports 09/03/2021

PMID: 33636110

Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity

Hoagland DA, Møller R, Uhl SA, Oishi K, Frere J, Golynker I, Horiuchi S, Panis M, Blanco-Melo D, Sachs D, Arkun K, Lim JK, tenOever BR.

Immunity 09/03/2021

PMID: 33577760